EEF1A2

Elongation factor 1-alpha 2 · Q05639 · EEF1A2 on Sugi Atlas →

20 patent compounds predicted against EEF1A2, 5 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL18022884 SCHEMBL18022884 0.35 2/20
SCHEMBL781368 SCHEMBL781368 0.45 1/20
SCHEMBL781369 SCHEMBL781369 0.45 1/20
SCHEMBL9755640 SCHEMBL9755640 0.41 1/20
SCHEMBL18022930 SCHEMBL18022930 0.40 1/20

Clinical trials — most relevant to EEF1A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From Real World PHASE4UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. PHASE1/PHASE2RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients PHASE2COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing PHASE1WITHDRAWN
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study) nanRECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Longitudinal Biomarkers With Selected Outcome Measures In CMT nanRECRUITING
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Speech and Short-term Memory Functions in Dyslexia: a Combined MEG and EEG Study nanUNKNOWN
Anesthetic Methods and Gene Expression Profile nanCOMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
CCM Italian Registry nanUNKNOWN
Gene Expression and Inflammation in Overweight Subjects nanCOMPLETED
ERA Test in Patients With Recurrent Implantation Failure nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EEF1A2 binder may also engage these)

ProteinNameSimilarity
Q32PH8 1.000 Q32PH8 →
P62631 1.000 P62631 →
P62632 1.000 P62632 →
A2Q0Z0 1.000 A2Q0Z0 →
P68105 1.000 P68105 →
P02993 1.000 P02993 →
P90519 1.000 P90519 →
Q59QD6 1.000 Q59QD6 →
P86939 1.000 P86939 →
P40911 1.000 P40911 →
Q8LPC4 1.000 Q8LPC4 →
P86933 1.000 P86933 →
Q9Y713 1.000 Q9Y713 →
P0DH99 1.000 P0DH99 →
Q0WL56 1.000 Q0WL56 →
P25166 1.000 P25166 →
Q41011 1.000 Q41011 →
P43643 1.000 P43643 →
P27592 1.000 P27592 →
P68103 1.000 P68103 →
EEF1A1 Elongation factor 1-alpha 1 1.000 landscape →
Q5VTE0 1.000 Q5VTE0 →
P27634 1.000 P27634 →
P17786 1.000 P17786 →
P0CT54 1.000 P0CT54 →
P34823 1.000 P34823 →
O42820 1.000 O42820 →
P0CT32 1.000 P0CT32 →
Q90835 1.000 Q90835 →
P17507 1.000 P17507 →